PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area


Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented an ambitious development strategy to take advantage of the rapidly evolving phage therapy area.

Go here to read the rest:
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

Related Posts